Phase 1 Stem Cell Transplantation Clinical Trials
12 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–12 of 12 trials
Recruiting
Phase 1Phase 2
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting
Phase 1
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Viral InfectionHematopoietic Stem Cell Transplantation (HSCT)Primary Immunodeficiency Disorders (PID)
Children's National Research Institute48 enrolled3 locationsNCT04691622
Recruiting
Phase 1
Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors
Hematopoietic Stem Cell Transplantation
Children's Hospital Medical Center, Cincinnati20 enrolled1 locationNCT07375290
Recruiting
Phase 1
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Phase 1
Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC
Hematologic MalignancyHaplo-identical Stem Cell Transplantation
University Hospital, Geneva12 enrolled1 locationNCT05066412
Recruiting
Phase 1
Phase I trial of multi-virus-specific T cells for paediatric haploidentical -stem cell transplant recipients
Haplo-identical haematopoietic stem cell transplantation
QIMR Berghofer Medical Research Institute20 enrolled1 locationACTRN12620000141943
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 10 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001501134
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 25 mg capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001492145
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12619001352190
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione capsule against the innovator 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione capsule conducted under fasting conditions in healthy male volunteers.
4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12619001338156
Completed
Phase 1
Infusion of virus specific immune cells in patients at the first sign of virus infection after a blood or bone marrow transplant who have received less than 7 days of anti-viral treatment.
Cytomegalovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationAdenovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationEpstein Barr Virus reactivation or infection following allogeneic blood or marrow stem cell transplantation
Western Sydney Local Health District31 enrolled3 locationsACTRN12618000343202
Recruiting
Phase 1
Infusion of donor-derived CMV peptide-specific CTL after allogeneic HSCT
Immune reconstitution post-allogeneic haematopoietic stem cell transplantation
Department of Haematology, Westmead Hospital12 enrolled1 locationACTRN12605000213640